Ann: Travelan to progress to Phase 3 Clinical Trials in the US, page-29

FYI - Product is on the market - OTC product. Not sure what your debating here. It wouldnt have gotten to phase 3 it showed minimal results. Lets just both admit we saw this today rather then at 0.066

Immuron’s record sales

Immuron (ASX:IMC) has just announced record sales (unaudited) for Travelan for the January period.

Year to date January sales were $2.7 million in total, which exceeded the peak full year FY20 sales of $2.5 million.

In Australia, sales of Travelan increased to $2.1 million in January, compared to $0.3 million in the pcp.

Travelan is an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract. It’s an orally administered immunotherapy that reduces the likelihood of contracting travelers’ diarrhoea.

Immuron previously reported that it had shipped inventory to Amazon for launch in US. The Amazon launch continues to progress well with sales ahead of budget.

Travelan is also a listed medicine on the Australian Register for Therapeutic Goods.

“We hope to get similar growth of the brand as we increase our investment and distribution in North America during the spring and summer vacation peak period,” said Immuron’s chief commercial officer, Flavio Palumbo.